Loading…
for educational and safety purposes
Methoxetamine and 2-Fluorodeschloroketamine both come up in the same conversations; they overlap on Glutamate and Pain. Methoxetamine: Methoxetamine (MXE) is an arylcyclohexylamine dissociative developed as a ketamine analog and widely sold as a research chemical before international bans. 2-Fluorodeschloroketamine: 2-Fluorodeschloroketamine (2-FDCK, 2F-DCK) is an arylcyclohexylamine dissociative and a fluorinated analog of ketamine in which the aromatic chlorine is replaced by fluorine, and it is presumed to share ketamine's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist.
Methoxetamine (MXE) is an arylcyclohexylamine dissociative developed as a ketamine analog and widely sold as a research chemical before international bans. It acts as a potent uncompetitive antagonist at the NMDA glutamate receptor, binding the phencyclidine site within the channel pore to produce dissociative, anesthetic, and psychotomimetic effects; unlike ketamine it also engages serotonergic systems, raising cortical and accumbal serotonin and relying partly on 5-HT2 receptors for some of its sensorimotor effects. Its longer duration and greater intensity relative to ketamine, marketed misleadingly as "bladder friendly," were accompanied by reports of abuse, urinary and cerebellar toxicity, and fatal intoxications. Paradoxically, preclinical work has also identified rapid antidepressant-like effects mediated through glutamatergic and AMPA-receptor signaling, mirroring ketamine.
2-Fluorodeschloroketamine (2-FDCK, 2F-DCK) is an arylcyclohexylamine dissociative and a fluorinated analog of ketamine in which the aromatic chlorine is replaced by fluorine, and it is presumed to share ketamine's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist. It has circulated widely as an inexpensive research chemical producing a broadly ketamine-like dissociative state, and its extensive metabolism has been mapped in human liver microsomes, urine, and hair, with nor-2F-DCK identified as a principal metabolite. Addictovigilance surveillance has linked ketamine analogues including 2-FDCK to serious neurological and psychiatric events and to recorded deaths, and case reports describe emergency presentations in a dissociated state after insufflation. Like other arylcyclohexylamines, it carries risks of compulsive redosing and, with chronic use, urinary tract and bladder toxicity.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
antagonist
Antagonist
reuptake inhibitor
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.